Litcius/Paper detail

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja, Joshua Bomsztyk, Shameem Mahmood, Brendan Wisniowski, Raakhee Shah, Anish Tailor, Kwee Yong, Rakesh Popat, Neil Rabin, Charalampia Kyriakou, Jonathan Sive, Simona Degli Esposti, Frank Larkin, Sarah Worthington, Alyse Hart, Emma Dowling, Nuno Correia, Ceri Bygrave, Andrzej Rydzewski, Krzysztof Jamroziak, Ashutosh Wechalekar

2022Blood Cancer Journal23 citationsDOIOpen Access PDF

Topics & Concepts

AmyloidosisMedicineAL amyloidosisInternal medicineSystemic therapyOncologyIntensive care medicineImmunologyCancerImmunoglobulin light chainBreast cancerAntibodyAmyloidosis: Diagnosis, Treatment, OutcomesMultiple Myeloma Research and TreatmentsProtein Kinase Regulation and GTPase Signaling
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis | Litcius